Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
Gilead Sciences Sovaldi (sofosbuvir) and GS-5816 cured about 95 percent of treatment-naive people with genotypes 1 through 6 of hepatitis C virus (HCV) who did not have cirrhosis in a recent trial. Aside from achieving excellent pan-genotypic results, the combination is also notable for successfully sidestepping the use of ribavirin. Results from the randomized Phase II GS-US-342-0102 study were presented at the 49th annual meeting of the European Association for the Study of the Liver (EASL) in London.
BUT Merck is kicking up some sand for the 3's - I just saw this somewhere - trial for 1's and 3's. Sofosbuvir + Merck drugs. (Gilead is doing VERY well with Sofos, eh? hehe)
http://clinicaltrials.gov/ct2/show/NCT02133131?term=Merck+AND+Hepatitis+C&recr=Open&no_unk=Y&rank=13
http://www.reuters.com/article/2014/08/15/achillion-hepatitisc-idUSL4N0QL3IO20140815